Navigation Links
Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiology's Annual Scientific Sessions
Date:3/19/2012

NEW BRUNSWICK, N.J., March 19, 2012 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Monday, March 26th at approximately 10:30 a.m., Eastern Time, to coincide with the American College of Cardiology (ACC) Annual Scientific Sessions in Chicago, Ill. 

Phase 3 results of the EINSTEIN-PE study in treating patients with acute symptomatic pulmonary embolism for the prevention of recurrent venous thromboembolism comparing rivaroxaban to today's standard of care, the combination of initial therapy with enoxaparin followed by Vitamin k antagonist, will be shown for the first time at ACC.

A pre-recorded webcast, with management from the company's subsidiaries, Janssen Research & Development, LLC, and Janssen Pharmaceuticals, Inc., will provide an update on the results of the EINSTEIN-PE study and an update on the initial launch of XARELTO® (rivaroxaban).

The webcast/podcast and replay can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations."


'/>"/>
SOURCE Johnson & Johnson
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
2. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
3. Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries
4. Johnson & Johnson Announces Support for Kohl-Grassley Physician Payments Sunshine Act of 2009
5. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
6. Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson
7. U.S. Files Suit Against Johnson & Johnson For Paying Kickbacks to Nations Largest Nursing Home Pharmacy
8. EF Johnson Technologies Announces Third Quarter Results
9. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
10. Johnson & Johnson to Participate in the 30th Annual Cowen and Company Health Care Conference
11. Two Johnson & Johnson Subsidiaries to Pay Over $81 Million to Resolve Allegations of Off-Label Promotion of Topamax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)...   Arena Pharmaceuticals, Inc. (NASDAQ: ... in the ralinepag phase 2 trial.  Ralinepag is an ... for the treatment of pulmonary arterial hypertension (PAH). The ... "This marks an important step in the development ... on our pipeline," said Amit Munshi , Arena,s ...
(Date:12/7/2016)... Conn. , Dec. 7, 2016 According to ... in more than one-third (38%) of patients with non-small cell ... epidermal growth factor receptor (EGFR) genetic mutation status. The findings ... ( LBA ID #6067 #P3.02b ) at the ... Vienna, Austria . The survey results revealed ...
(Date:12/7/2016)... LONDON , Dec. 7,2016  Based ... drug delivery industry, Frost & Sullivan recognizes ... Frost & Sullivan Award for Enabling Technology ... plug the loopholes in traditional drug delivery ... and liquid microneedle-based drug delivery technologies, Memspatch ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Augustine ... services to families and business owners in the greater Dallas metropolitan area, is ... Dallas Fallen Officer Foundation. , Established in 2009 by active police professionals in ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Sharon Kleyne, ... Global Climate Change and Your Health on Voice of America, declared on her radio ... call attention to the fact that when these bullies attack leaders in corporate America, ...
(Date:12/7/2016)... ... 07, 2016 , ... 1105 Media’s Live From program has ... Awards competition. Live From won in the Use of Social Media category. The ... projects undertaken by the media industry’s most innovative marketing professionals. , ...
(Date:12/7/2016)... ... 2016 , ... Maureen McLaughlin, LA.c., a certified acupuncturist, is ... Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with fertility patients to ... their family building goals. Acupuncture helps fertility patients by supporting the ...
(Date:12/7/2016)... Va. (Dec. 3, 2016) , ... (PRWEB) December ... ... nation’s only patient advocacy nonprofit for individuals impacted by cerebral cavernous angiomas, was ... in New Mexico with a patient engagement program. New Mexico has more people ...
Breaking Medicine News(10 mins):